Company Overview and News

Stock With Momentum: Ranhill Holdings

2018-10-04 theedgemarkets - 1
Ranhill Holdings Bhd (-ve) TRADING of shares in Ranhill Holdings Bhd (fundamental: 1.1/3, valuation: 2.4/3) triggered our momentum algorithm yesterday for the second time in the last two months. The counter closed up 4.5 sen or 4.89% at 96.5 sen yesterday with a market capitalisation of RM857.23 million. A total of 13.89 million shares changed hands, compared with the stock’s 200-day average volume of 898,135.

Nik Norzul Thani takes over as chairman of Pengurusan Aset Air Berhad

2018-10-03 malaymail
KUALA LUMPUR, Oct 3 — Former Al Rajhi Bank Malaysia chairman Datuk Seri Nik Norzrul Thani is now the chairman of Pengurusan Aset Air Berhad (PAAB).
4588 1058 5272

Trading ideas: Versatile, AMMB, Sunway, Paramount, Ranhill, MCT

KUALA LUMPUR: Versatile Creative Bhd , AMMB Holdings Bhd , Sunway Bhd , Paramount Corp Bhd, Ranhill Holdings Bhd and MCT Bhd are among the stocks to watch on Thursday, according to JF Apex Research.
4995 1015 AMMHF 5272

Sime Darby Plantation, PetChem, E&O, MCT, Taliworks, Ranhill, Versatile Creative, AMMB, Sunway and Paramount

2018-08-21 theedgemarkets
KUALA LUMPUR (Aug 20): Based on corporate announcements and news flow today, companies that will be in focus on Thursday (Aug 23) may include: Sime Darby Plantation Bhd, Petronas Chemicals Group Bhd, Eastern & Oriental Bhd, MCT Bhd, Taliworks Corp, Ranhill Holdings Bhd, Versatile Creative Bhd, AMMB Holdings Bhd, Sunway Bhd and Paramount Corp Bhd.
4995 1015 5183 PECGF AMMHF 5272

RM12.76m suit against Ranhill unit dropped

2018-08-21 theedgemarkets
KUALA LUMPUR (Aug 21): Ranhill Holdings Bhd said today a suit filed in China against its wholly-owned unit Ranhill Water Technologies (Cayman) Ltd (RWTC) by Wahtoting Holding Ltd has been dropped.
5272 BSMAF 1818

Johor to get new water company, MB says

2018-08-13 malaymail
ISKANDAR PUTERI, Aug 13 — The Johor government is planning to establish a new water utility company to regulate tariffs that won’t burden its people, Johor Mentri Besar Datuk Osman Sapian said today.

Ranhill up 4.41% on higher 2Q earnings

2018-08-10 theedgemarkets
KUALA LUMPUR (Aug 10): Ranhill Holdings Bhd shares rose 4.41% this morning after it posted a 6.6% rise in net profit to RM15.43 million for the second quarter ended June 30 from RM14.51 million or 1.63 sen a year ago.

Ranhill Q2 net profit 6.3% higher

Moving forward, the Ranhill said it targets to own and operate gross 1,000MW power plants that deliver clean energy, and 3,000 million litres per day (MLD) of water and wastewater treatment capacity, of which 700 MLD is to be from the international segment by 2022.

KLCI seen opening flat, to hover above 1,790-level

2018-08-09 theedgemarkets
KUALA LUMPUR (Aug 10): The FBM KLCI is seen opening flat today in line with the weaker overnight close at Wall Street, but hover above the 1,790-level.
5843 5029 5216 SPMXY 7251 5225 SPMXF 5176 5272 Q0F IHHHF

Supermax, Gamuda, KPS, Sunway REIT, Bintai Kinden, Far East, Datasonic, Velesto, Barakah Offshore, MyEG, Ranhill, Asdion and IHH

2018-08-09 theedgemarkets
KUALA LUMPUR (Aug 9): Based on corporate announcements and news flow today, stocks in focus tomorrow may include the following: Supermax Corp Bhd, Gamuda Bhd, Kumpulan Perangsang Selangor Bhd (KPS), Sunway Real Estate Investment Trust, Bintai Kinden Corp Bhd, Far East Holdings Bhd, Datasonic Group Bhd, Velesto Energy Bhd, Barakah Offshore Petroleum Bhd, My EG Services Bhd, Ranhill Holdings Bhd, Asdion Bhd and IHH Healthcare Bhd.
7251 SPMXF 5176 5272 532843 5843 5029 5216 SPMXY 5225 FORTIS Q0F IHHHF

Ranhill 2Q net profit improves slightly with higher water consumption

2018-08-09 theedgemarkets
KUALA LUMPUR (Aug 9): Johor-based water and utilities firm Ranhill Holdings Bhd has registered a 6.6% rise in net profit to RM15.43 million or 1.74 sen per share for the second quarter ended June 30 from RM14.51 million or 1.63 sen a year ago.
5272 BSMAF 1818

Trading ideas: Ranhill, Hua Yang, Ikhmas Jaya, Tek Seng

KUALA LUMPUR: JF Apex Research expects Ranhill Holdings Bhd , Hua Yang Bhd , Ikhmas Jaya Group Bhd and Tek Seng Holdings Bhd to be among the stocks to watch following their latest news.
5062 5272 5268 7200

KLCI to trend higher, immediate hurdle at 1,755

2018-07-18 theedgemarkets
KUALA LUMPUR (July 19): The FBM KLCI is expected to trend higher today, tracking the overnight gains at most global markets, with immediate hurdle at 1,755 points.
7073 0101 5062 6459 5272 5268 7200

Maxis, Seacera, Sapura Energy, MNRB, TMC Life Sciences, Ranhill, Hua Yang, Ikhmas Jaya, Menang Corp and Tek Seng

2018-07-18 theedgemarkets
KUALA LUMPUR (July 18): Based on corporate announcements and news flow today, companies that may be in focus on Thursday (July 19) may include the following: Maxis Bhd, Seacera Group Bhd, Sapura Energy Bhd, MNRB Holdings Bhd, TMC Life Sciences Bhd, Ranhill Holdings Bhd, Hua Yang Bhd, Ikhmas Jaya Group Bhd, Menang Corp (M) Bhd and Tek Seng Holdings Bhd.
7073 0101 5062 6459 5272 BSMAF 5268 7200 1818

Ranhill's associate bags 3-year contract in Sabah's KPOC-Kebabangan platform

2018-07-18 theedgemarkets
KUALA LUMPUR (July 18): Perunding Ranhill Worley Sdn Bhd (PRW), an associate of Ranhill Holdings Bhd and WorleyParsons Ltd of Australia, has won a contract from Kebabangan Petroleum Operating Co Sdn Bhd (KPOC) to provide engineering support and design services to the KPOC-Kebabangan northern hub platform in Sabah.

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...